AGC Biologics begins operations at new manufacturing building in Copenhagen

The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors

AGC and Medinet sign agreement for cell therapy CDMO business

A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan

AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability

Development services for gene and cell therapies is planned to begin first in 2025

AGC to establish Life Science Company in 2023

The Group will continue to make proactive investments of its management resources in the life science business

AGC begins study to expand its Bio-CDMO capability in Japan

AGC to invest $100 million for expanding synthetic pharmaceutical production in Spain

The new facility is scheduled to start operation in the first half of 2024

Trivitron Healthcare sets up ultrasound manufacturing facility in India

The ultrasound products manufactured in the new manufacturing facility will be sold under the brand name SonoRad, and are designed for large hospitals, healthcare institutions and individual radiology centres

Stelis Biopharma appoints Mark W. Womack as CEO

He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations

Mark W. Womack is the new CEO of Stelis Biopharma

He will be stationed at the company HQ in Bengaluru, India